VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
VYNE Therapeutics Inc. (Nasdaq: VYNE) will announce its third-quarter financial results for the period ending September 30, 2021, on November 10, 2021, before market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VYNE Therapeutics Inc. (Nasdaq: VYNE) will announce its third-quarter financial results for the period ending September 30, 2021, on November 10, 2021, before market opening. A conference call and webcast will take place at 8:30 AM ET to discuss the results and provide updates on corporate developments. VYNE aims to improve patient lives through innovative therapies for immuno-inflammatory conditions and has a pipeline including FMX114 for atopic dermatitis.
Positive
- VYNE is developing innovative therapies for high unmet medical needs in immuno-inflammatory conditions.
- The company has a proprietary pipeline, including FMX114 for atopic dermatitis.
Negative
- None.
Details
News Market Reaction – VYNE
The recorded move for VYNE in the trading session of this news was +1.59%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.
| Conference Call Details: | |
| Wednesday, November 10th @ 8:30am Eastern Time | |
| Toll Free: | 855-327-6837 |
| International: | 631-891-4304 |
| Conference ID: | 10017178 |
| Webcast: | https://themediaframe.com/mediaframe/webcast.html?webcastid=44cKOFEX |
A replay of the call will be archived on the Company’s website at www.vynetherapeutics.com after the conference call.
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. VYNE is working to develop and commercialize a variety of therapies for major immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s unique and proprietary pipeline includes FMX114 for the treatment of mild-to-moderate atopic dermatitis and access to a library of bromodomain & extra-terminal (BET) domain inhibitors in both topical and oral forms for the treatment of major immuno-inflammatory conditions and rare skin diseases.
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations:
Joseph Ranieri
LifeSci Advisors, LLC
617-430-7582
joer@lifesciadvisors.com
Tyler Zeronda
Chief Financial Officer
VYNE Therapeutics
908-458-9106
tyler.zeronda@vynetx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.